Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

The proposed recommendations are intended to safely expedite approvals of promising therapies for multiple myeloma, but one expert is skeptical about the likelihood of industry compliance.

Patients with non-secretory myeloma, a disease affecting a relatively small number of individuals, can face obstacles including difficulties in receiving a diagnosis, a scarcity of available clinical ...

Multiple myeloma patients have a fivefold increased risk of infections compared to healthy controls, with sepsis and pneumonia being the most prevalent. The study found a 70% infection risk in MM ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

The initial diagnostic workup should include a history and physical examination, as well as some baseline laboratory studies (Figure 2-1). The initial diagnostic workup should include a history and ...

The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...